

[New Drug Approvals](#)

Generic Name (Trade Name—Company)

June 5, 2018

Pegfilgrastim-jmdb

(Fulphila—Mylan GmbH)

First pegfilgrastim biosimilar helps reduce the risk of infection during cancer treatment

Uses/Notes

FDA approved [pegfilgrastim-jmdb](#) as the first biosimilar to pegfilgrastim (Neulasta) to decrease the chance of infection as suggested by febrile neutropenia in patients with nonmyeloid (non–bone marrow) cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence of febrile neutropenia.

FDA's approval of the new biosimilar was based on a review of evidence that included extensive structural and functional characterization, animal study data, human pharmacokinetic and pharmacodynamic data, clinical immunogenicity data, and other clinical safety and effectiveness data that demonstrates pegfilgrastim-jmdb is biosimilar to pegfilgrastim. It has been approved as a [biosimilar](#), not as an [interchangeable product](#).

The most common adverse effects are bone pain and pain in extremities. Patients with a history of serious allergic reactions to human granulocyte colony–stimulating factors such as pegfilgrastim or filgrastim products should not take the new biosimilar.

Serious adverse effects from treatment include rupture of the spleen, acute respiratory distress syndrome, serious allergic reactions including anaphylaxis, acute inflammation of the kidney, an abnormally high level of white blood cells, capillary leak syndrome, and the potential for tumor growth. Fatal sickle cell crises also have occurred.

Source URL:

<http://blog.pharmacist.com/new-drug-approvals/first-pegfilgrastim-biosimilar-helps-reduce-risk-infection-during-cancer>

APhA DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in APhA DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.